T he importance of estrogen as a regulator of plasma lipid metabolism has been most clearly demonstrated in settings of estrogen deficiency (eg, menopause). Bilateral ovariectomy in premenopausal women causes an increase in plasma levels of low-density lipoprotein (LDL) when compared with premenopausal women with preserved ovaries. 1 Furthermore, LDL cholesterol levels increase after onset of menopause. 2 Multiple mechanisms have been proposed by which estrogens regulate lipoprotein metabolism in humans, including induction of hepatic LDL receptor expression, 3,4 reduction of hepatic secretion of acyl-coenzyme A: cholesterol acyltransferase 2-derived cholesteryl esters in plasma lipoproteins, 5 reduction of hepatic lipase, 6 and reduction of levels of proprotein convertase subtilisin kexin type 9 (PCSK9), 7 a key regulator of LDL receptor metabolism. 8 The receptor(s) mediating estrogen's effects on LDL metabolism is unclear. Estrogen's effects are triggered via 2 main receptor types. Classic estrogen receptors (ERs) have been shown to have both nuclear and cytoplasmic/membraneassociated sites of effect. 9,10 More recently, a G-proteincoupled receptor, G-protein ER (GPER; aka GPR30) has been shown to mediate some of the so-called rapid (nongenomic) effects of estrogen. 11 We have recently shown that GPER is also activated by aldosterone. 12
The role of GPER in hepatic lipid metabolism is unknown. GPER is expressed in normal hepatocytes. 13 Notably, mice with genetic deletion of GPER have increased cholesterol levels. 14 In contrast, total cholesterol levels have not been reported to be elevated in ERα knockout mice. 15 To examine the relationship between GPER function and lipid metabolism in humans, we have studied the effect of carrying a common hypofunctional GPER genetic variant. The P16L GPER genetic variant is common with an allelic frequency in the general population of ≈20%. Recent studies from our laboratory have shown that this proline to leucine change at amino acid residue 16 of GPER (http://www.ncbi.nlm.nih.gov/SNP/snp_ref. cgi?rs=11544331) results in a hypofunctional response to the GPER agonist G1. 16 In these studies, we evaluate the association of GPER P16L genotype with plasma LDL cholesterol in a previously characterized, 17 genetically isolated population of Northern European descent from Alberta (n=415). To validate our findings, we examine a London, Ontario-based population of healthy women (n=339). 18 We found that in both population samples, the hypofunctional GPER P16L variant was associated with increased LDL concentrations in women, following a recessive model. Furthermore, in cellular studies, we demonstrate that G1 agonist activation of GPER in HepG2 cells, which endogenously express GPER, 19, 20 leads to reduced PCSK9 expression and increased LDL receptor expression. Overall, these studies support an important role of GPER in regulation of plasma lipoprotein metabolism.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

Female Carriers of GPER P16L Have Higher Plasma LDL Cholesterol
In the discovery cohort, the GPER P16L allele frequency was 12.3%, with no significant difference between men (13.1%) and women (11.7%). The frequencies of CC, CT, and TT genotypes were 77.1%, 21.2%, and 1.7%, respectively; these did not significantly deviate from the Hardy-Weinberg distribution. The body mass index and waist circumference were not different between genotypes ( Table 1 ). The plasma LDL and total cholesterol concentrations in this sample were significantly higher in homozygotes for the P16L allele, and followed an apparent recessive model (P<0.05; Table 2 ). After adjusting for covariates, there was no change in the significance of the associations (Table 3 ).
Subgroup analysis showed that the increase in LDL cholesterol levels in carriers of the GPER P16L variant was sex specific; in particular, women but not men showed the increase in plasma LDL and total cholesterol levels ( Table 2) . After adjusting for covariates in women, there was no change in the significance of the associations (Table 3 ).
In the validation cohort of 339 women, the allele frequency of the P16L GPER variant was 25.2%. The frequencies of GPER variant genotype were 56.3%, 36.9%, and 6.8%, respectively, for wild type (CC), heterozygote (CT), and P16L homozygote (CT) and did not significantly deviate from the Hardy-Weinberg distribution. The plasma LDL cholesterol levels were significantly higher in those carrying the P16L GPER variant (TT>CT>CC; P<0.05; Table 4 ). The body mass index and waist circumference did not vary significantly between genotypes ( Table 5 ). The increase in plasma LDL cholesterol levels associated with the expression of the P16L GPER variant remained significant after adjusting for covariates (Table 6) . 
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Role of GPER in the Regulation of LDL Receptor Protein Expression
To determine whether the increase in LDL cholesterol levels in carriers of the GPER P16L variant might indicate a role for GPER in the regulation of lipoprotein metabolism, we studied whether GPER activation regulated LDL receptor protein expression, which is an important determinant of plasma LDL levels. 21 In HepG2 cells, the GPER agonist, G1 22 , induced a concentration-dependent increase in LDL receptor protein expression with a maximal effect of a 36±6% (mean±SE; n=10) increase in LDL receptor protein above baseline at a G1 concentration of 0.1 μmol/L ( Figure 1 ); this was comparable with the increase in LDL receptor protein induced by atorvastatin (33±9%, n=3; Figure 1 ). 23 To confirm the GPER dependence of the observed effect of G1, we examined the effect of the GPER antagonist, G15 24 (1 μmol/L) on G1-mediated stimulation of LDL receptor protein expression. Pretreatment of HepG2 cells with G15 inhibited the G1-mediated increase in LDL receptor ( Figure 2 ). G15 alone had no significant effect on LDL receptor protein expression. In addition, G15 had no significant effect on atorvastatin-mediated upregulation of LDL receptor protein ( Figure 2 ).
In addition, we confirmed the GPER-dependent effect of G1 on LDL receptor protein expression using a GPERtargeted shRNA to downregulate GPER expression. Infection of HepG2 cells with the adenoshGPER construct resulted in ≈50% downregulation of GPER mRNA content when compared with the control construct (adenosh-GFP; Figure 3A ). GPER downregulation, using shGPER, attenuated G1-mediated increase in LDL receptor protein expression ( Figure 3B ). Atorvastatin-mediated LDL receptor upregulation was not affected by shRNA-induced GPER downregulation.
Role of GPER on Regulation of LDL Uptake and LDL Receptor mRNA
To confirm the functional effect of GPER activation on LDL receptor protein expression, we assessed G1-mediated regulation of LDL uptake. G1 induced a concentration-dependent increase in LDL uptake with a maximal response of 27±2% above control at G1 concentrations >0.1 μmol/L (n=4; P<0.05; Figure 4A ).
To determine whether the increase in LDL receptor protein expression and LDL uptake was related to an increase in LDL receptor mRNA, we performed quantitative polymerase chain reaction studies. No alterations in LDLR mRNA levels were apparent at G1 concentrations ranging from 1 nmol/L to 1 μmol/L (n=3). In contrast, atorvastatin increased LDL receptor mRNA levels 57±14% above control (n=4; P<0.05; Figure 4B ).
Role of GPER in the Regulation on PCSK9 Expression
PCSK9 is recognized as a critical regulator of overall LDL receptor functional capacity. 8 Furthermore, the regulation of PCSK9 levels has been shown to be cAMP dependent, 25 which is the second messenger pathway regulated by GPER activation. 26 To determine whether GPER plays a role in PCSK9 protein expression, which in turn could explain the effects of GPER on the regulation of LDL receptor protein, we examined the effect of G1 on PCSK9 levels as assessed in HepG2 conditioned media samples. G1 mediated a concentration-dependent decrease in PCSK9 protein expression in HepG2 cells, with a maximal decrease to 72±8% (n=8) of control with G1 at a concentration of 1.0 μmol/L ( Figure 5A ). Atorvastatin, in contrast, increased PCSK9 protein content by 40% (P<0.05). Comparable findings were obtained when PCSK9 content was assessed in samples taken from cell lysates ( Figure 5B ).
To determine whether the decrease in PCSK9 protein expression was related to a decrease in PCSK9 receptor mRNA, we performed quantitative polymerase chain reaction studies. G1 mediated a concentration-dependent decrease in PCSK9 mRNA content ( Figure 5C ). In contrast (and as expected), atorvastatin treatment increased PCSK9 mRNA content.
To confirm the GPER dependence of the observed effect of G1, we examined the effect of G15 (1 μmol/L). Pretreatment of HepG2 cells with G15 significantly attenuated the decrease in PCSK9 protein induced by G1 ( Figure 6 ). G15 alone had no significant effect on PCSK9 protein expression. In addition, G15 had no significant effect on atorvastatin-mediated upregulation of PCSK9 protein expression. Furthermore, we confirmed the GPER-dependent effect of G1 on PCSK9 levels using the GPER-targeted shRNA. GPER downregulation almost completely attenuated the G1-mediated decrease in PCSK9 expression ( Figure 7) . The atorvastatinmediated PCSK9 upregulation was not affected by GPER downregulation.
Discussion
The importance of the G-protein-coupled receptor, GPER, in mediating the vascular effects of estrogen (and of aldosterone) has been increasingly appreciated. [27] [28] [29] [30] [31] However, the importance of GPER in regulation of lipoprotein metabolism in humans has been unexplored to date. Using a combination of human genetics and functional cellular biology, we found that the relatively common missense GPER P16L had a significant influence on LDL cholesterol concentrations. Specifically, the GPER P16L genotype was associated with higher plasma LDL cholesterol levels in women, but not in men. Furthermore, in HepG2 cells expressing GPER, we demonstrate that GPER activation (1) increased LDL receptor protein expression, without change in mRNA content and (2) decreased PCSK9 mRNA content and protein levels. These independent lines of experimental evidence are directionally consistent and in aggregate support the importance of GPER as a regulator of LDL metabolism, probably via regulation of PCSK9. Consistent with a functional effect of the GPER P16L variant, human genetic association studies showed higher LDL cholesterol levels in female carriers. In the northern Alberta sample, heterozygotes and homozygotes for L16 had ≈0.1 and ≈1.0 mmol/L higher plasma LDL cholesterol concentrations, respectively, than homozygotes for P16. This is equivalent to or higher than the effect sizes seen for other relatively common candidate gene variants in lipid metabolism, [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] (although much smaller than the effect sizes seen in carriers of rare mutations associated with familial hypercholesterolemia). 42 Notably, the effect on LDL cholesterol of the GPER P16L allele was less marked (although still clearly evident) in the London, Ontario validation cohort. The reason for the lesser effect size in the Ontario sample in comparison with the Alberta cohort is unclear. Notably, both populations were ethnically similar (ie, predominantly white from Western European origins). However, it should be noted that in the London sample, the LDL determination was performed on a nonfasting sample, which may have minimized the apparent effect of carrying the GPER P16L allele.
It is notable that the GPER P16L genotype is associated with higher LDL cholesterol in women only. GPER was initially characterized as mediating the effects of estrogen, 11 hence an effect of expression of a hypofunctional GPER leading to increased LDL cholesterol solely in women would not be unexpected. However, our recent studies demonstrated that aldosterone is also a potent GPER agonist. 12 If so, it might have been expected that the effect on LDL cholesterol of expressing a hypofunctional GPER might have been comparably apparent in men and women. The reason for this apparent inconsistency is unclear. We considered why this genetic variant has not been previously identified as a significant determinant on prior genome-wide association studies of plasma LDL cholesterol levels. However, as far as we have been able to determine, none of the commonly used microarrays in the catalogue of published genome-wide association studies carried the single nucleotide polymorphism of interest (rs11544331) (https://www.genome.gov/page.cfm?p ageid=26525384#searchForm). [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] In this context, the findings in the present study emphasize that the previous genome-wide association studies may be incomplete about potential candidate genes in dyslipidemia because the associations are limited to the content on the microarray. A recent genome-wide association study 57 did identify a variant of GPR146 (viz., rs1997243) as being associated with cholesterol levels ( Table II in the onlineonly Data Supplement) . Notably, this genetic variant was also reported to be in linkage disequilibrium with P16L GPER (r 2 =0.554), supporting our present findings.
These studies suggest a mechanism whereby GPER activation has beneficial effects on LDL cholesterol metabolism-and thus specify a mechanism by which carrying a hypofunctional GPER variant may lead to increased LDL cholesterol levels. LDL receptor expression is significantly increased by GPER activation with effects comparable with those of HMG (3-hydroxy-3-methyl-glutaryl) CoA reductase inhibition.
In summary, our studies demonstrate that the expression of a common GPER genetic variant parallels increased LDL levels and that GPER activation increases LDL receptor protein expression, probably via downregulation of PCSK9 levels. The findings could explain, at least in part, the relationship between functional estrogen deficiency and increased LDL cholesterol. They also show that the GPER P16L variant has a clearly distinct effect on LDL cholesterol, without any apparent associated or concomitant effect on HDL cholesterol concentrations, which are also well known to be associated with estrogen status. Overall, these findings support an important role of GPER in the regulation of LDL metabolism in humans. . G-protein estrogen receptor (GPER) downregulation and its effect on G1-mediated decrease in proprotein convertase subtilisin kexin type 9 (PCSK9) expression. shGPER-mediated downregulation of GPER expression caused an attenuation in the G1-mediated decrease (0.1 μmol/L) in PCSK9 expression (data represent the mean±SE of 3 independent experiments performed for each condition) Inset, Representative immunoblot demonstrating the G1-mediated decrease and atorvastatin-mediated increase in PCSK9 expression vs control in both shGFP-and shGPERinfected cells. *P<0.05 vs its respective control (ie, cells infected with the same adenosh construct, treated with vehicle only).
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